Search research articles
Contact Us
Filters
Showing results (51-60 of 66) with videos related to
Page
of 7
Sort By:
The Lancet. Haematology
|
December 22, 2015
Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study
David Valcárcel, Guillermo Sanz, Margarita Ortega, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 13, 2017
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
Juan-Jose Lahuerta, Bruno Paiva, Maria-Belen Vidriales, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 21, 2021
Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL-Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia
Lara Maria Gómez García, Adela Escudero, Carmen Mestre, et al.
The American Journal of Pathology
|
September 15, 2012
Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials
Bruno Paiva, María-Belén Vídriales, María-Ángeles Montalbán, et al.
Blood
|
December 1, 2011
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
Bruno Paiva, Norma C Gutiérrez, Laura Rosiñol, et al.
Annals of Hematology
|
January 7, 2021
Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients
Kamila Janusz, Marta Martín Izquierdo, Félix López Cadenas, et al.
Frontiers in Immunology
|
May 21, 2026
MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics
Rocío Maseda, María Carmen Arriba, Lucía Martínez-Santamaría, et al.
Leukemia & Lymphoma
|
August 20, 2013
Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes
Blanca Xicoy, María-José Jiménez, Olga García, et al.
The Lancet. Oncology
|
August 27, 2010
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
María-Victoria Mateos, Albert Oriol, Joaquín Martínez-López, et al.
Blood Advances
|
July 10, 2026
Germline landscape stratification defines distinct molecular and prognostic groups in therapy related myeloid neoplasms
Oriol Calvete, Julia Mestre, Lorea Chaparro-González, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 66) with videos related to
Sort By:
Page
of 7
The Lancet. Haematology
|
December 22, 2015
Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study
David Valcárcel, Guillermo Sanz, Margarita Ortega, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 13, 2017
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
Juan-Jose Lahuerta, Bruno Paiva, Maria-Belen Vidriales, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 21, 2021
Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL-Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia
Lara Maria Gómez García, Adela Escudero, Carmen Mestre, et al.
The American Journal of Pathology
|
September 15, 2012
Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials
Bruno Paiva, María-Belén Vídriales, María-Ángeles Montalbán, et al.
Blood
|
December 1, 2011
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
Bruno Paiva, Norma C Gutiérrez, Laura Rosiñol, et al.
Annals of Hematology
|
January 7, 2021
Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients
Kamila Janusz, Marta Martín Izquierdo, Félix López Cadenas, et al.
Frontiers in Immunology
|
May 21, 2026
MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics
Rocío Maseda, María Carmen Arriba, Lucía Martínez-Santamaría, et al.
Leukemia & Lymphoma
|
August 20, 2013
Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes
Blanca Xicoy, María-José Jiménez, Olga García, et al.
The Lancet. Oncology
|
August 27, 2010
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
María-Victoria Mateos, Albert Oriol, Joaquín Martínez-López, et al.
Blood Advances
|
July 10, 2026
Germline landscape stratification defines distinct molecular and prognostic groups in therapy related myeloid neoplasms
Oriol Calvete, Julia Mestre, Lorea Chaparro-González, et al.
Page
of 7